33643-94-6

Usage

Uses

Used in Organic Synthesis:
4-Hydroxy-2-phenylpyrimidine is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its unique structure and functional groups make it a valuable building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Hydroxy-2-phenylpyrimidine is utilized as a precursor in the development of new drugs. Its versatile chemical properties allow it to be incorporated into various drug molecules, potentially leading to the discovery of novel therapeutic agents.
Used in Agrochemicals:
4-Hydroxy-2-phenylpyrimidine is employed in the agrochemical sector for the synthesis of active ingredients in pesticides and other crop protection products. Its chemical properties enable it to be modified and tailored to target specific pests or diseases, improving the effectiveness of these agrochemicals.
Used in Dye Industry:
In the dye industry, 4-Hydroxy-2-phenylpyrimidine is used as a starting material for the production of various dyes and pigments. Its ability to form colored compounds makes it a valuable component in the creation of a wide range of colorants for different applications, including textiles, plastics, and printing inks.

InChI:InChI=1/C10H8N2O/c13-9-6-7-11-10(12-9)8-4-2-1-3-5-8/h1-7H,(H,11,12,13)

Upstream product

• 141-90-2 2-thiouracil 
• 960-16-7 tributylphenylstannane 
• 5751-20-2 2-Methylthiouracil 
• 618-39-3 benzamidin 
• 623-47-2 propynoic acid ethyl ester 
• 15934-46-0 benzamidene hydrochloride 
• 33630-20-5 2-phenyl-4-methoxypyrimidine 
• 59938-07-7 (3E)-1,1,1-trichloro-4-ethoxybut-3-en-2-one 
• 1670-14-0 benzamidine monohydrochloride 
• 151227-74-6 1-oxido-1-phenyl-4-cyano-4-triphenylphosphonio-2-aza-1,3-butadiene 
• 98-88-4 benzoyl chloride 
• 14735-70-7 diexo-3-Aza-4-oxotricyclo<4.2.1.0^2,5>non-7-ene 
• 825-60-5 benzimidic acid ethyl ester 

Downstream Products

• 1266476-82-7 N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-ethynyl-2-phenyl-pyrimidin-4-amine 
• 1266479-98-4 4,5-dibromo-2-phenylpyrimidine 
• 1266480-05-0 N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-5-((trimethylsilyl)ethynyl)pyrimidin-4-amine 
• 1266480-03-8 tert-butyl 5-cyclopropyl-3-(5-iodo-2-phenylpyrimidin-4-ylamino)-1H-pyrazole-1-carboxylate 
• 1266477-07-9 (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-(3-methoxyprop-1-enyl)-2-phenyl-pyrimidin-4-amine 
• 26786-28-7 5-bromo-4-hydroxy-2-phenylpyrimidine 
• 1266480-00-5 5-iodo-2-phenylpyrimidin-4-ol 
• 1266480-01-6 4-bromo-5-iodo-2-phenylpyrimidine 
• 1266480-02-7 N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-iodo-2-phenylpyrimidin-4-amine 
• 1266480-04-9 tert-butyl 5-cyclopropyl-3-(2-phenyl-5-((trimethylsilyl)ethynyl)pyrimidin-4-ylamino)-1H-pyrazole-1-carboxylate 
• 1266476-75-8 5-bromo-N-(5-cyclopropyl-2H-pyrazol-3-yl)-2-phenyl-pyrimidin-4-amine 
• 14790-42-2 4-chloro-2-phenylpyrimidine 
• 26786-28-7 5-bromo-2-phenyl-3H-pyrimidin-4-one 

Relevant academic research and scientific papers

Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead

Oncogenic activation of RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary thyroid carcinoma, and non-small-cell lung cancer. Currently approved RET inhibitors were not originally designed to be RET inhibitors, and their potency against RET kinase has not been optimized. Hence, novel compounds able to inhibit both wild-type RET (wtRET) and its mutants (e.g., V804MRET) are needed. Herein we present the development and the preliminary evaluation of a new sub-micromolar wtRET/V804MRET inhibitor, N-(2-fluoro-5-trifluoromethylphenyl)-N′-{4′-[(2′′-benzamido)pyridin-4′′-ylamino]phenyl}urea (69), endowed with a 4-anilinopyridine structure, starting from our previously identified 4-anilinopyrimidine hit compound. Profiling against a panel of kinases indicated 69 as a multi cKIT/wtRET/V804MRET inhibitor.

Synthesis of mono- and diaza-'pyridones' via stille coupling of alkoxystannanes

Various alkoxy-substituted heterocyclic stannanes provide access to the corresponding substituted 'pyridone' moieties via Stille cross-coupling. Both pyridyl and a series of diazinyl stannanes are prepared, and options for unmasking (via demethylation or debenzylation) of the pyridone unit are evaluated. Georg Thieme Verlag Stuttgart. New York.

PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS

The present invention relates to compounds II useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the invention.

Desulfitative cross-coupling of protecting group-free 2-thiouracil derivatives with organostannanes

We here report a unique and efficient copper bromide mediated pallado-catalyzed coupling of protecting group-free 2-thiouracil derivatives with organostannanes. The nature of the copper appears to be crucial for successful cross coupling.

A convenient synthesis of 5- and 6-substituted 2-phenyl-3H-pyrimidin-4-ones

A simple and convenient one-pot procedure for the synthesis of 5- and 6-substituted 2-phenyl-3H-pyrimidin-4-ones by the condensation of 4-alkoxy-1,1,1-trichloroalk-3-en-2-ones with benzamidine hydrochloride is described. Georg Thieme Verlag Stuttgart.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic beta cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS

The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

A Facile Method for the Preparation of 2-Substituted Pyrimidin-4(3H)-ones by a Retro-Diels-Alder Reaction

diexo-3-Aza-4-oxotricyclo2.5>non-7-ene (1) reacted with carboximidic esters by ring expansion to yield tricyclic 5,6-dihydropyrimidin-4(3H)-ones 3; when the latter were refluxed in chlorobenzene solution, cyclopentadiene split off to gi